For patients’ sake, collaborate already

Cancer immunotherapy companies must stop squandering the most precious stakeholder, patients, and collaborate now on platform trials to test new combination regimens. A straightforward platform trial design that tests different combo partners with PD-1/PD-L1 agents could save companies time, money and get even greater advancements to patients faster.

Combination studies account for the largest portion of the thousands of ongoing PD-1/PD-L1 trials, as companies aim to gain a foothold in immuno-oncology or extend their franchise...